Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF02244072PMID 1672458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.

  2009cited by this paper
• Psychomotor stimulant effects of the stereoisomers of chlorpheniramine

  2005cited by this paper
• Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia

  2005cited by this paper
• Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia

  2004cited by this paper
• Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man

  2004cited by this paper
• A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial

  1990cited by this paper
• Pharmacokinetics of remoxipride in elderly psychotic patients

  1990cited by this paper
• Clinical pharmacokinetics of remoxipride

  1990cited by this paper
• Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography.

  1990cited by this paper
• Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients.

  1990cited by this paper
• Remoxipride — a new potential antipsychotic compound

  1989cited by this paper
• Remoxipride — a new potential antipsychotic drug

  1988cited by this paper
• Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.

  1984cited by this paper
• Serum concentrations of thioridazine, its major metabolites and serum neuroleptic‐like activities in schizophrenics with and without tardive dyskinesia

  1982cited by this paper
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities.

  1982cited by this paper
• Understanding the Dose-Effect Relationship

  1981cited by this paper
• High serum neuroleptic levels in tardive dyskinesia?

  1979cited by this paper

• Systemic- and direct nose-to-brain transport in the rat; a pharmacokinetic model for remoxipride after intravenous and intranasal administration

  2011cites this paper
• Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration

  2011cites this paper
• Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.

  2006cites this paper
• Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.

  1995cites this paper
• Influence of the dosing interval on prolactin release after remoxipride.

  1995cites this paper
• New drugs for the treatment of schizophrenia.

  1993cites this paper
• An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients

  1993cites this paper
• Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.

  1991cites this paper